Insider Cluster (2 insiders) ·Filed Jun 3, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 2 insiders, $1.4M total
Actionable Insight • Neutral

Insider sales are routine option-exercise tax-withholding transactions. Do not read bearish signal. Monitor upcoming quarterly earnings (likely August 2026) for pipeline progress on Tyvaso and any clinical data readouts — those are the material catalysts for UTHR, not this cluster.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
UTHR ▼ -6.15% at T+60d
NEUTRAL call ✗ call lost -6.15% · α vs SPY -7.77% · entry $547.22 → $513.54
Entry anchored
Jun 3, 2026
via day open
T+1d
-0.16%
call -0.16% · α +2.44%
$546.37
settled 4mo ago
T+5d
-0.33%
call -0.33% · α +2.22%
$545.40
settled 4mo ago
T+20d
+1.59%
call +1.59% · α +3.21%
$555.91
settled 3mo ago
T+60d
-6.15%
call -6.15% · α -7.77%
$513.54
settled 5w ago

Price Chart

Loading chart...

Executive Summary

CEO Martine Rothblatt and CFO James Edgemond sold a combined ~$1.41M in UTHR shares over five trading days, entirely from exercised options. These are routine same-day stock-for-tax sales (cashless exercises) — not open-market liquidation of unrestricted shares. At 0.006% of UTHR's $22.9B market cap, the dollar value is trivial and carries no informational signal. Multiple past neutral-scored UTHR reports have negative T+20 alpha (historical win rate 17%), consistent with the model underperforming on this name. The cross-filing actuarial verdicts show near-uniform amplification for this combo type, but the standalone economics of these sales are too small to warrant an impact override.

Key Financial Metrics

Direction
selling
Insiders
2

Key Facts

  • CEO Martine Rothblatt sold 2,820 shares total at ~$535-562 over 3 trading days, all from option exercises at exercises at $0 and $146.03 per share.
  • CFO James Edgemond sold 3,200 shares total at ~$545-561 over 2 trading days, all from option exercises at exercises at $0 and $117.76 per share.
  • Total open-market sale proceeds: ~$2.5M (includes proceeds from shares sold same-day as option exercise). Net cash received by insiders after strike costs: ~$1.41M.
  • All sales are same-day sale-to-cover transactions from option exercise — routine tax-withholding pattern, not discretionary portfolio liquidation.
  • Total sale value is 0.006% of UTHR's $22.9B market cap — economically trivial.
  • Historical UTHR reports show a T+20 win rate of 17% and average negative alpha of -6.51%, suggesting prior scoring patterns have underperformed on this name.
  • The SCORE CALIBRATION block does not apply (scores 2-4 neutral filings have no conditional-p metric in this segment).

Financial Impact

Total open-market sales proceeds of ~$1.41M (net of strike costs) — 0.006% of market cap. Trivial.

Risk Factors

  • The historical T+20 alpha for UTHR neutral-rated reports is -6.51% — this stock has underperformed model expectations systematically, but the signal has been from event timing and forward guidance, not insider sales.
  • CEO Rothblatt sold shares at an average of ~$545, near 52-week highs — but the pattern is consistent with her regular option-exercise cadence.
  • No open-market purchases alongside these sales to offset selling signal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1780518915452
91 reports for UTHR
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +5.53%Feb 25, 2026
Filters
Rows
Reports for UTHR — sortable, filterable
TypeNow
Sep 15, 2026
17d ago
Insider Cluster
NEUTRAL ★ 2/10
$500.35 $497.31▼ −0.61%▼ −2.72%$573.51 (+14.62%)
Sep 11, 2026
21d ago
Insider Cluster
NEUTRAL ★ 3/10
$497.11 $494.63▼ −0.50%▼ −0.28%$573.51 (+15.37%)
Sep 10, 2026
22d ago
Insider Cluster
MIXED ★ 4/10
$503.86 $497.27▼ −1.31%▼ −0.81%$573.51 (+13.82%)
Sep 9, 2026
23d ago
Insider Cluster
NEUTRAL ★ 3/10
$506.82 $498.48▼ −1.65%▼ −0.99%$573.51 (+13.16%)
Sep 4, 2026
28d ago
Insider Cluster
NEUTRAL ★ 2/10
$487.61 $502.70▲ +3.09%▲ +4.30%$573.51 (+17.62%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$488.16 $497.11▲ +1.83%▲ +2.98%$573.51 (+17.48%)
Aug 28, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$515.46 $487.61▼ −5.40%▼ −5.51%$573.51 (+11.26%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$527.91 $492.02▼ −6.80%▼ −6.03%$573.51 (+8.64%)
Aug 26, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$516.68 $492.02▼ −4.77%▼ −4.65%$573.51 (+11.00%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$516.68 $492.02▼ −4.77%▼ −4.65%$573.51 (+11.00%)
Showing 10 of 91

US Market Status

Market Open — Closes in 6h 24m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 3, 2026